亚洲 · 股市与财经 · The Investor

Korea’s first homegrown GLP-1: Can Hanmi’s Eppe undercut Mounjaro and Wegovy?

来源：The Investor · 韩国 22 小时前

Hanmi Pharmaceutical’s Eppe is poised to challenge Wegovy and Mounjaro in Korea’s fast-growing obesity drug market, with price emerging as a potentially decisiv ...

在 The Investor 阅读全文登录后可收藏

MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.theinvestor.co.kr)

Korea’s first homegrown GLP-1: Can Hanmi’s Eppe undercut Mounjaro and Wegovy?

推荐阅读

Best bank stock to buy amid Q2 business updates: PNB, Canara, Union Bank, Indian Bank or Bandhan? Target Prices

Hao Mart owner resisting OG’s mortgage foreclosure on his GCB

Nifty Outlook for October 6: Will bears use index bounce as a selling opportunity on weekly expiry?

TVS ASL raises ₹425 crore from Crescent Enterprises in Series D round

Is joining EPS a must at Rs 25K+ salary?

ภาวะตลาดอนุพันธ์:แกว่งผันผวน แม้คลายกังวลเฟดอาจเลื่อนขึ้นดอกเบี้ย แต่ผลน้ำท่วมยังกดดัน

Korea’s first homegrown GLP-1: Can Hanmi’s Eppe undercut Mounjaro and Wegovy?

分享

推荐阅读

Best bank stock to buy amid Q2 business updates: PNB, Canara, Union Bank, Indian Bank or Bandhan? Target Prices

Hao Mart owner resisting OG’s mortgage foreclosure on his GCB

Nifty Outlook for October 6: Will bears use index bounce as a selling opportunity on weekly expiry?

TVS ASL raises ₹425 crore from Crescent Enterprises in Series D round

Is joining EPS a must at Rs 25K+ salary?

ภาวะตลาดอนุพันธ์:แกว่งผันผวน แม้คลายกังวลเฟดอาจเลื่อนขึ้นดอกเบี้ย แต่ผลน้ำท่วมยังกดดัน